Abstracts tagged "Crystal-induced arthritis"

Abstract Number: 183 • 2014 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound Reveals Calcific Deposition Arthropathy in Seronegative Inflammatory Arthritis Patients
Sheila L. Arvikar¹, Janice Lin² and Minna J. Kohler³, ¹Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ²Dermatology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Allergy, and Immunology, Massachusetts General Hospital / Harvard Medical School, Boston, MA
Background/Purpose Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) have vastly improved the diagnosis of rheumatoid arthritis (RA), but the diagnosis and management of seronegative…
Abstract Number: 2000 • 2013 ACR/ARHP Annual Meeting
Changes In The Prevalence Of Gout In The United States General Population Between 1960 and 2010: The National Health and Nutrition Examination Surveys
Eswar Krishnan and Linjun Chen, Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Despite the widely shared impression that the prevalence of gouty arthritis (gout) has increased over time in the US few population data are available.…
Abstract Number: 1722 • 2013 ACR/ARHP Annual Meeting
Does Starting Allopurinol Prolong Acute Treated Gout?
Erica Hill¹, Jay B. Higgs², Karen Sky³, Michelle Sit⁴ and Angelique N. Collamer⁵, ¹Rheumatology, San Antonio Military Medical Center, Fort Sam Houston, TX, ²Rheumatology, San Antonio Military Medical Center, JBSA - Fort Sam Houston, TX, ³Rheumatology, US Department of Veterans Affairs, Alaska VA Healthcare System, Anchorage, AK, ⁴Subspecialty Clinic - Rheumatology, David Grant Medical Center, Travis AFB, CA, ⁵Internal Medicine, Langley AFB Hospital, Langley AFB, VA
Background/Purpose: Gout is a common cause of morbidity in the US population. Traditionally, allopurinol is not initiated during an acute episode to avoid prolonging…
Abstract Number: 1901 • 2012 ACR/ARHP Annual Meeting
Chronic Gout. Improvement According to Outcome Meaures in Rheumatology Domains in Daily Clinical Practice
Janitzia Vazquez-Mellado¹, Betsabé Serrano¹, Jaime Mendoza², Sergio Garcia-Mendez¹, V.Chantal Hernández¹, Virginia Pascual Ramos³, Ruben Burgos-Vargas¹ and Marina Rull-Gabayet², ¹Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Dept de Immunología y Reumato, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: OMERACT has proposed domains to evaluate the effect of treatment in patients with acute and chronic gout. Their frequency, time to improve and percentage…
Abstract Number: 1661 • 2012 ACR/ARHP Annual Meeting
CCR1 Potentiates Gouty Inflammation Following Initial CXCR2-Dependent Neutrophil Recruitment to Sites of Monosodium Urate Crystal Deposition in Mice
Robert P. Friday¹, Terry K. Means², Melissa Tai², Christian D. Sadik² and Andrew D. Luster³, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, MA, ³Massachusetts General Hospital, Charlestown, MA
Background/Purpose: During attacks of acute gouty arthritis, monosodium urate (MSU) crystals elicit a potent neutrophilic inflammatory response in the affected joint, causing exquisite pain and…
Abstract Number: 1629 • 2012 ACR/ARHP Annual Meeting
Microarray Analysis of Acute and Intercritical Gout
Alicia Rodriguez-Pla¹, Lynda Bennett¹, Kathryn H. Dao², Edwardo Delgado³, Typhanie Maurouard¹, M. Virginia Pascual⁴ and John J. Cush⁵, ¹Baylor Healthcare System, Baylor Institute for Immunology Research, Dallas, TX, ²Rheumatology, Baylor Research Institute, Dallas, TX, ³Arthritis Care and Research Center, Dallas, TX, ⁴Baylor Institute for Immunology Research, Dallas, TX, ⁵Baylor Research Institute, Dallas, TX
Background/Purpose: We aimed to identify the immune mechanism underlying gouty inflammation using microarrays analysis and modular gene expression signatures. Methods: Whole blood along with clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].